SUMMARY In a randomised double-blind trial over one year oral BCG has been compared with a control preparation in the treatment of chronic Crohn's disease. Overall assessment scores deteriorated in nine of 22 patients taking BCG, and 11 of 26 in the control group (P = 0-25); this deterioration was great enough to be regarded as a clinical relapse in three patients taking BCG and in seven taking the control preparation (P > 0 1). No significant benefit from oral BCG treatment has been demonstrated.
There is evidence that some patients with Crohn's disease are anergic. In an attempt to stimulate the immune response, Geffroy and his colleagues (Geffroy et al., 1977) used BCG to treat Crohn's disease and the results of their preliminary studies were sufficiently encouraging to justify a controlled trial. This paper reports a double-blind comparison of oral Pasteur BCG with placebo in treatment of chronic Crohn's disease with special reference to the prevention of relapse.
Methods

SELECTION OF PATIENTS
All patients were attending St Mark's Hospital, London, or the Hopital Charles-Nicolle, Rouen, fulfilled published criteria for the diagnosis of Crohn's disease (Lennard-Jones, 1971) , and gave informed consent. Of the 50 patients, 29 were diagnosed on clinical, radiological, and, where possible, biopsy evidence as having inactive or mildly active Crohn's disease. The remaining 21 patients had been treated by one or more resections of diseased intestine with pathological confirmation of the diagnosis, but in every case residual (including anal) or recurrent intestinal disease was known to be present. A previous trial had shown that these patients with chronic Crohn's disease, who were not receiving other treatment, were the most likely to relapse and were therefore most suitable for assessing the effectiveness of BCG (Multicentre Trial, 1977) .
Patients were excluded from the trial if a struc-'Present address: Department of Therapeutics, City Hospital,
Received for publication 24 August 1978 tural complication of Crohn's disease such as stenosis with obstruction or abscess formation was present, or if regular outpatient follow-up was impossible. As a precaution, all patients had a radiograph of the chest to exclude active pulmonary tuberculosis and electrophoresis of serum proteins to exclude hypogammaglobulinaemia (Mande, 1968) .
TREATMENT
Current treatment with corticosteroids, azathioprine, sulphasalazine, or long-term antibacterial drugs excluded a patient from the trial. Deterioration of the disease so that any of these treatments was judged necessary constituted a failure of the trial treatment and the trial ended. Short-term treatment with an antibacterial drug for coincidental infection, nutritional supplements such as vitamins or iron, and symptomatic treatment such as antidiarrhoeal drugs, antispasmodics, or analgesics were permitted.
Patients were allocated randomly to receive Pasteur BCG (Immuno 1JCG-F), 75 mg/ampoule, or 3 % methyl cellulose, 5 ml/ampoule, which closely resembled the active vaccine. The ampoules were stored in a domestic refrigerator and patients were taught to add the contents of one to four ampoules to fruit juice immediately before taking the contents by mouth. O 00000 00000000
Change in -1 0 00 total score -2 0000 -3. glutinin in Crohn's disease (Ng and Vicary, 1976) and can cause positive conversion of the tuberculin test. Levamisole restores depressed leucocyte migration to normal (Segal et al., 1977) in Crohn's disease and may stimulate immunity.
The rationale of treating Crohn's disease by enhancing the immune response is thus based on an uncertain premise. Drugs with immunosuppressant properties may also be effective. Corticosteroids are of proven benefit in active Crohn's disease but not in reducing the relapse rate (Singleton 1977) . Azathioprine does not appear beneficial in active Crohn's disease (Rhodes et al., 1971; Klein et al., 1974; Singleton, 1977) but in some studies the drug apparently reduces the relapse rate and may allow a maintenances dose of corticosteroids to be reduced (Willoughby et al., 1971; Rosenberg et al., 1975; O'Donoghue et al., 1978) .
BCG has been used to enhance cellular immunity in oncology with some success. In leukaemia or solid tumours, the vaccine is administered by repeated scarification rather than by mouth. The oral route has been used for immunisation against tuberculosis (Mand , 1968) . This route was chosen for the present study because repeated scarification can be disfiguring, preliminary studies suggested that the oral route may be effective and effectiveness may depend on locally induced immunity in the gut. Pasteur BCG, especially prepared for oral administration, was used because it had been used in the pilot studies and because its immunostimulant effect is particularly potent (Mackaness et al., 1973) . The doses selected were arbitrary but in line with those used in early studies.
Patients with chronic inactive or mildly active disease were chosen for the trial because the use of a live vaccine precluded the use of corticosteroids or azathioprine. It was known that the risk of relapse was higher in these patients than in those treated surgically without evidence of residual disease (Multicentre Trial, 1977) . In the event, one-fifth of the patients relapsed during the year.
The scoring system used for assessing results was designed before the introduction of the 'Crohn's disease activity index' (Best et al., 1976) which uses weighted criteria. The symptoms and signs used for assessment in the present system were the same as in the index, except for the inclusion of rectal bleeding and the omission of a factor for drug treatment of diarrhoea. The 'activity index' weights highly diarrhoea, abdominal pain, and sense of well-being.
Scores in the present system appear lower than in the activity index because of the absence of weighting factors. The only laboratory value used in the 'activity index' is the haematocrit; our system includes haemoglobin, white cell count, ESR, and serum albumin. Scores associated with relapse tend to be relatively low because usually only a few of the many possible symptoms, signs, and laboratory values become abnormal.
Results of the trial showed a slight trend in favour of the active vaccine but very large numbers of patients would be needed to provide convincing evidence of any possible activity. The need to restrict other treatments, the possible dangers and the administrative difficulties suggest that oral BCG will not be clinically useful in chronic Crohn's disease. However, the treatment proved to be safe and well tolerated. Tuberculin conversion was inconstant. The use of BCG by other routes, in a different dose, or of other treatments to enhance immunity may warrant trial. 
